Sickle cell patients push on access to future CRISPR cures; how states can keep people insured after Medicaid cuts

Taking stock of the drug industry, from the lab to the medicine chest

March 7, 2023 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Courtesy Royal Society With CRISPR cures on horizon, sickle cell patients ask hard questions about who can access them With CRISPR cures for sickle cell disease on the horizon, the gene-editing world must grapple with tough questions of equity and access. By Megan Molteni How can states keep people insured after Medicaid protections lapse? Connecticut has an idea Connecticut officials recruited diverse candidates to ensure people in underserved communities have access to advice about health insurance. By Rachel Cohrs STAT+ | In Theranos's backyard, a health tech leader takes another crack at better blood tests Stanford's Michael Snyder has developed a way to collect tiny samples of blood for more frequent testing. He gets the Theranos comparisons. By Mohana Ravindranath JIM WATSON/AFP via Getty Images Biden proposes expanding Medicare drug negotiation program The Biden administration wants to expand Democrats' new drug pricing law by allowing Medicare to negotiate prices for more drugs. By Rachel Cohrs How one medical school became remarkably diverse — without considering race in admissions At UC-Davis, the 1972 medical class was mostly white and male. The class of 2026 is among the most diverse in the nation — without race-based admissions. By Usha Lee McFarling

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser